68765-53-7

Usage

Uses

Used in Organic Synthesis:
4-bromo-N1-phenylbenzene-1,2-diamine serves as a crucial intermediate in organic synthesis, facilitating the production of a variety of complex organic molecules. Its unique structure allows for further chemical reactions, making it a valuable component in the synthesis of specialized compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-bromo-N1-phenylbenzene-1,2-diamine is utilized as a building block for the development of new drugs. Its structural properties make it a promising candidate for the design of molecules with specific therapeutic effects, contributing to the advancement of medicinal chemistry.
Used in Dye Production:
4-bromo-N1-phenylbenzene-1,2-diamine also finds application in the production of dyes, where its chemical structure contributes to the color and stability of the dyes produced. This makes it an important component in the manufacturing of various dye products used in different industries.
Used in Industrial Chemicals:
4-bromo-N1-phenylbenzene-1,2-diamine is a component in the formulation of various industrial chemicals, where its chemical properties are leveraged to enhance the performance of these products.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-bromo-N1-phenylbenzene-1,2-diamine is explored as a potential drug target for the treatment of certain diseases. Its unique structure and properties make it a subject of interest for research aimed at understanding and developing new therapeutic agents.
Used in Biological Systems Research:
4-bromo-N1-phenylbenzene-1,2-diamine is employed in research to study the structure-activity relationship of biological systems. This helps scientists to gain insights into how different molecules interact with biological targets, which is essential for the development of effective drugs and therapies.

Upstream product

• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 62-53-3 aniline 
• 16588-25-3 4-bromo-2-nitro-N-phenylaminobenzene 

Downstream Products

• 1169709-30-1 C₁₉H₁₄Br₂N₂O 
• 760212-55-3 5-bromo-1,2-diphenyl-1H-benzo[d]imidazole 
• 221636-18-6 5-Bromo-1-phenyl-1H-benzoimidazole 
• 260258-95-5 5-(2-methylsulfanyl-pyrimidin-4-yl)-1-phenyl-1H-benzoimidazole 
• 260258-92-2 4-(1-phenyl-1H-benzoimidazol-5-yl)-1H-pyridin-2-one 
• 260258-97-7 4-(1-phenyl-1H-benzoimidazol-5-yl)-pyrimidin-2-ol 
• 221636-04-0 4-(1-phenyl-1H-benzoimidazol-5-yl)-phenol 
• 221636-03-9 1-phenyl-5-(4-methoxyphenyl)benzimidazole 
• 260258-91-1 1-phenyl-5-pyridin-4-yl-1H-benzoimidazole 

Relevant academic research and scientific papers

Novel polyheterocyclic compound and application thereof in organic light-emitting device

The invention belongs to the technical field of organic light-emitting display, and particularly relates to a novel polyheterocyclic compound and application thereof in an organic light-emitting device. The structure of the novel polyheterocyclic compound provided by the invention is shown as a formula (I). The compound has good thermal stability, and when the compound is applied to an OLED deviceand used as a green light host material, the photoelectric property of the device can be effectively improved. The OLED device containing the polyheterocyclic compound can be applied to the field ofdisplay or illumination.

Bipolar material and organic light emitting diode element

The invention provides a bipolar material in which carbazole is linked with benzimidazole carbon nitrogen and an organic light emitting diode element utilizing the bipolar material. The organic lightemitting diode element comprises a substrate, a first conducting layer, an electric hole transfer layer, a light emitting layer, an electronic transfer layer and a second conducting layer, wherein thefirst conducting layer is arranged on the substrate; the electric hole transfer layer is arranged on the first conducting layer; the light emitting layer is arranged on the electric hole transfer layer and comprises the bipolar material in which carbazole is linked with benzimidazole carbon nitrogen; and the electronic transfer layer is arranged on the electronic transfer layer.

Neutral iridium(iii) complexes bearing BODIPY-substituted N-heterocyclic carbene (NHC) ligands: Synthesis, photophysics,: In vitro theranostic photodynamic therapy, and antimicrobial activity

The synthesis, photophysics, and photobiological activities of a series of novel neutral heteroleptic cyclometalated iridium(iii) complexes incorporating boron dipyrromethene (BODIPY) substituted N-heterocyclic carbene (NHC) ligands (Ir1-Ir5) are reported. The effect of the substitution position of BODIPY on the NHC ligands, either on C4 of the phenyl ring (Ir1-Ir3) or C5 of the benzimidazole unit (Ir4 and Ir5), and its linker type (single or triple bond) on the photophysical properties was studied. Ir1-Ir5 exhibited BODIPY-localized intense 1IL (intraligand transition)/1MLCT (metal-to-ligand charge transfer) absorption at 530-543 nm and 1,3IL/1,3CT (charge transfer) emission at 582-610 nm. The nanosecond transient absorption results revealed that the lowest triplet excited states of these complexes were the BODIPY-localized 3π,π? states. Complexes Ir4 and Ir5 exhibited blue-shifted 1IL absorption and 1,3IL/1,3CT emission bands compared to the corresponding absorption and emission bands in complexes Ir1 and Ir3. However, replacing the methyl substituents on N3 of benzimidazole in complexes Ir1 and Ir4 with oligoether substituents in Ir3 and Ir5, respectively, did not impact the energies of the low-energy absorption and emission bands in the corresponding complexes. Water-soluble complexes Ir3 and Ir5 have been explored as photosensitizers for in vitro photodynamic therapy (PDT) effects toward human SKMEL28 melanoma cells. Ir3 showed no dark cytotoxicity (EC50 > 300 μM) but good photocytotoxic activity (9.66 ± 0.28 μM), whereas Ir5 exhibited a higher dark cytotoxicity (20.2 ± 1.26 μM) and excellent photocytotoxicity (0.15 ± 0.01 μM). The phototherapeutic indices with visible light (400-700 nm) activation were >31 for Ir3 and 135 for Ir5. Ir3 and Ir5 displayed 1O2 quantum yields of 38% and 22% in CH3CN, respectively, upon 450 nm excitation. Ir5 was more effective at generating reactive oxygen species (ROS) in vitro. Ir5 was also active against Staphylococcus aureus upon visible light activation, with a phototherapeutic index of >15 and EC50 value of 6.67 μM. These photobiological activities demonstrated that these neutral Ir(iii) complexes are promising in vitro PDT reagents, and substitution at C5 on the benzimidazole group of the NHC ligand was superior to C4 substitution on the phenyl ring.

A heterocyclic ligands containing compounds and methods for their preparation, application (by machine translation)

The present invention provides a compound containing heterocyclic ligands and its preparation method, an electroluminescent device. The present invention provides heterocycle-containing ligand compound, through the particular selection of heterocyclic ligands and different metal binding, can adjust the wavelength of the compound, the organic metal compound used in the organic electroluminescent device, to make the device light-emitting efficiency is improved, and the service life is long. (by machine translation)

Compound with heterocyclic ligand and preparation method and application thereof

The invention provides a compound with a heterocyclic ligand and a preparation method and application thereof. According to the compound with the heterocyclic ligand, the specific heterocyclic ligand is selected to be combined with metal aluminum, so that after the obtained organic compound is applied to an organic light-emitting device, the light-emitting efficiency of the device is improved, and the service life is long.

Lithium compound with heterocyclic ligand and preparation method and application thereof

The invention provides a lithium compound with a heterocyclic ligand and a preparation method and application thereof. According to the lithium compound with the heterocyclic ligand, the specific heterocyclic ligand is selected to be combined with metal lithium, so that after the obtained organic lithium compound is applied to an organic light-emitting device, the light-emitting efficiency of the device is improved, and the service life is long.

Organic Electroluminescent Compounds and Organic Electroluminescent Device Comprising the Same

The present invention relates to organic electroluminescent compounds and an organic electroluminescent device comprising the same. The organic electroluminescent compounds of the present invention can manufacture the organic electroluminescent device having excellent driving lifespan, and improved current efficiency and power efficiency since driving voltage is low.COPYRIGHT KIPO 2015

ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

Fused bicyclic mTOR inhibitors

Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.

Design and synthesis of 1,5-diarylbenzimidazoles as inhibitors of the VEGF-receptor KDR

1,5-Diarylbenzimidazoles have been identified as potent inhibitors of KDR kinase activity. The series was developed with a goal of finding compounds with optimal drug-like properties. This communication describes structural modifications in the series that enhance solubility, lower protein binding, and provide compounds with excellent potency and pharmacokinetic profiles.